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Objective: To assess the outcome of vacuum-assisted wound closure
(VAC®) therapy for infected bypass grafts.
Methods: A retrospective 7-year review of patient records from 2004
to 2011 of all patients receiving VAC® therapy for infected bypass grafts.
Results: Thirty-seven patients with 42 wounds and 45 infected bypass
(28 synthetic) grafts received VAC® treatment. Two serious bleeding epi-
®sodes from the suture lines occurred. The median VAC therapy time was
20 days. The proportion of patent bypass grafts was 91% (41/45) at a
T
hedian time of 3.5 months from the start of VAC® therapy. Five patients
ith seven bypasses had persistent infection or re-infection, and the total
raft preservation rate was 76% (34/45). The median follow-up time was 15
onths. The presence of two infected bypass grafts in one groin wound was
ssociated with an increased major amputation rate (hazard ratio (HR) 7.4
95% confidence interval (CI) 2.0–27.5]), and synthetic graft infection (HR
.0 [95% CI 1.5–17.4]) and non-healed wound (HR 3.6 [95% CI 1.5–8.7])
ere associated with mortality.
Conclusion:VAC® therapy of infected bypass grafts was able to induce
ffective wound healing without compromising the early bypass function.
wo infected synthetic bypasses in the wound were associated with the
ighest risk of adverse outcome.
